Abstract: The present invention relates to a water-soluble, multicompartment unit dose article comprising at least two superposed compartments, wherein the compartments are formed by sealing water soluble film to contain liquid detergent composition. The water-soluble film comprises polyvinyl alcohol polymer comprising an anionic polyvinyl alcohol copolymer, or a blend of polyvinyl alcohol copolymers. The total volume of the liquid detergent composition is from 12 ml.

Abstract: The present invention relates to a water-soluble, multicompartment unit dose article comprising at least two superposed compartments, wherein the compartments are formed by sealing water soluble film to contain liquid detergent composition. The water-soluble film comprises polyvinyl alcohol polymer comprising polyvinyl alcohol resin and wherein the polyvinyl alcohol resin comprises an homopolymer. The total volume of the liquid detergent composition is from 10 ml to 20 ml.

Abstract: A computer-implemented method for controlling and/or monitoring yeast propagation includes providing a mixture of yeast cells and wort, determining an original gravity of the wort or of the mixture and a temperature of the mixture at a start time, and calculating a theoretical end time for the yeast propagation on the basis of a logistic propagation model for the yeast propagation, on the basis of the original gravity and on the basis of the temperature at the start time.

Abstract: The disclosure provides a method of producing a finished, aged distilled spirit, and a method of producing bottles of a distilled spirit that employ in-bottle finishing. In one embodiment, the method of producing a finished, aged distilled spirit includes: (1) placing an aged distilled spirit in a bottle, (2) placing a wood piece in the bottle, wherein the wood piece is used for in-bottle finishing of the aged distilled spirit and is rested in a non-alcoholic liquid before the placing of the wood piece, and (3) sealing the bottle, having located within the bottle both the aged distilled spirit and the wood piece.

Abstract: Pretreating hops includes soaking hops in whiskey for a period of time until the hops absorb a portion of the whiskey and begin to swell. These pretreated hops are in the form of hop flowers, a hop extract, a concentrated hop resin or liquid, or combinations thereof. In any case, the pretreated hops take on the flavors and aromas of the whiskey. A beer product is described that uses these pretreated hops added during the boil stage of brewing the beer, during fermentation of the beer, and/or after fermentation of the beer. Adding the pretreated hops during the brewing process results in the flavors and aromas from the whiskey imparting to the beer. The process obviates the requirement for finishing the beer in whiskey barrels or adding whiskey to the beer product after manufacturing to obtain a complex flavor profile.

Abstract: The subject matter of this application is using novel biological reactors for the fermentation of gases into liquid products. More specifically, the subject matter relates to the use of a Multiple-Pass Trickle Bed Reactor (MP-TBR) for the anaerobic or aerobic and biological fermentation of gases generated from industrial processes and/or from the gasification of biomass and other organic carbon sources. The products may include, but are not limited to, ethanol and other valuable chemicals.

Abstract: The present apparatus is a hybrid system that can use human tissue and/or cells coupled with a hydrogel and can use tissue explants (biopsies). The system is implemented in an embodiment by use of an actuator and a holder. The actuator is implemented with a one or more of chambers of a plurality of shapes, with each chamber addressable by an associated single inlet. In one embodiment, the holder comprises one or more independent chambers where cells or biopsies can be placed. In one embodiment, the holder is coupled to the actuator via the use of guides, threads, and the like that allow one part to slide into the other.

Abstract: A device for fabricating a perfusable three-dimensional tissue construct includes a chamber in which the tissue construct may be cultivated, the chamber including an inlet and an outlet for perfusing the tissue construct, and a sacrificial scaffold fixed in the chamber. The sacrificial scaffold includes a thermo-responsive polymer, the thermo-responsive polymer being not dissolvable in water at human body temperature and becoming dissolvable in water at a temperature below 30° C. The sacrificial scaffold includes at least one filament extending from the inlet to the outlet such that dissolution of the sacrificial scaffold provides for a liquid channel from the inlet to the outlet. The sacrificial scaffold seals the inlet and/or the outlet such that dissolution of the sacrificial scaffold after receiving a cultivation matrix in the chamber provides for a liquid channel from the inlet to the outlet through the cultivation matrix. Methods of use and manufacture are also disclosed.

Abstract: Provided are cell niche engineering platform which represents a valuable in vitro tool for investigating physiological and pathological cellular activities, an all-in-one technology to engineer cell niche (particularly soluble cell niche factors) with retained bioactivities, a mask-free, non-contact, biocompatible and multiphoton-based microfabrication and micropatterning method for engineering a spatially and quantitatively controllable soluble proteins/bioactive factors and cell-cell adhesion molecules. An universal cell niche engineering platform is provided that contributes to reconstituting heterogeneous native soluble cell niche for signal transduction modeling and drug screening studies.

Abstract: Improved cell culture devices and related methods that overcome the limitations of prior devices and methods, by creating devices that can integrate a variety of novel attributes. These various attributes include the use of gas permeable material and medium volumes that exceed conventional devices as well as compartments that can facilitate the long term study of high density cultures with reduced disruption of the culture environment, the ability to study the migration of items of interest including substances such as chemokine, track the movement of cells, and monitor cell to cell interactions.

Abstract: A cell culturing system is equipped with a cell culturing device and a support device. The cell culturing device comprises a culturing unit and a sampling unit. The support device includes a housing and a sampling support unit. The housing includes an accommodation chamber in which the culturing unit is accommodated. A sampling circuit unit is capable of being attached to and detached from the sampling support unit. The sampling support unit is installed on the outer surface of the housing.

Abstract: A cell culturing system includes a cell culturing device and a support device. The cell culturing device cultures cells by allowing a culture medium inside circulation flow paths connected to the bioreactor to flow inside the bioreactor. The cell culturing device is connected to the circulation flow paths and includes a waste liquid flow path in order to discard the liquid flowing through the circulation flow paths, and a waste liquid accommodation unit in which the liquid guided from the waste liquid flow path is accommodated. A sampling unit, in which the culture medium that is guided from the circulation flow paths to the waste liquid flow path is collected, is connected to the waste liquid flow path.

Abstract: Photoreceptor scaffolds that can be used for transplantation of organized photoreceptor tissue, with or without retinal pigment epithelial cells, which may improve grafted cell survival, integration, and functional visual rescue are disclosed herein. The scaffolds include a cell support layer having at least one honeycomb-shaped reservoir fluidly connected to a plurality of through-holes and at least one cell in the at least one honeycomb-shaped reservoir.

Abstract: A cell mass-forming member that is capable of easily forming a cell mass and superior in industrial mass productivity; a culture container equipped with the cell mass-forming member; a method for producing cultured cells using the cell mass-forming member; and cultured cells with a cell mass-forming member that are equipped with the cell mass-forming member. The cell mass-forming member has a base material, an adhesion inhibition area and a cell adhesion area are formed on the surface of the base material; a micro-concavo-convex structure area including a plurality of convex portions is formed in the cell adhesion area; and a hydrophilic coating layer is formed on both the adhesion inhibition area and the cell adhesion area. The culture container and the cultured cells with a cell mass-forming member are equipped with the cell mass-forming member. The method for producing cultured cells includes using the cell mass-forming member.

Abstract: The invention discloses a quasi in-vivo testing method using a uniquely designed multichambered bioblock apparatus. Cells are placed inside a top chamber fitted with a pore size membrane that allows certain cells to migrate through the pores into a bottom chamber holding a substrate. The portion of cells migrating from the top chamber and interacting with the substrate surface in a real time physiological quasi in vivo environment can be used to determine both the migratory response of specific cell types to selected attractive surfaces and the effect of the migratory cells on the surface over selected times of exposure.

Abstract: An apparatus for bioprocessing includes a housing, a drawer receivable within the housing, the drawer including a plurality of sidewalls and a bottom defining a processing chamber, and a generally open top, the drawer being movable between a closed position in which the drawer is received within the housing, and an open position in which the drawer extends from the housing enabling access to the processing chamber through the open top, and at least one bed plate positioned within the processing chamber and configured to receive a bioreactor vessel.

Abstract: A separation device for separating a solid separation target contained in a suspension obtained by suspension culture of adherent cells by using a fine scaffold material, and a separation method. The separation device has a separation chamber having a first chamber and a second chamber, and the first chamber and the second chamber are divided by a mesh structure for separation. The mesh structure for separation has mesh-holes with a predetermined size to suppress passage of the separation target, and a mesh structure for separation is configured in the separation chamber such that the liquid in the aforementioned suspension has a vertically upward directional component in the advancing direction of the liquid when the liquid passes through the mesh-holes.

Abstract: Some fluid coupling devices described herein are configured for use in fluid systems. For example, some embodiments described in this document are single-use, aseptic fluid coupling devices that can be coupled to create a sterile flow path therethrough. Some such aseptic couplings are genderless couplings such that two identical aseptic couplings can be coupled together and then latched to form a robust connection between the aseptic couplings.

Abstract: The invention relates to a comparison unit (130) configured for determining if a first pH measuring device of a first tank (104; 106) is affected by a pH-measuring problem, the comparison unit being configured for: receiving a first CO2 concentration and a first pH value, the first CO2 concentration being a CO2 concentration of a first gas volume above a medium in a first tank, the first CO2 concentration and the first pH value being measured at a first time when the medium in the first tank is in pH-CO2 equilibrium state with the first gas volume and before said equilibrium state is modified by the metabolism of a cell culture in the first tank, the first pH value being a measured value provided by a first pH measuring device operatively coupled to the first tank (102); receiving a second CO2 concentration and a second pH value, the second CO2 concentration being a CO2 concentration of a second gas volume above a medium in a second tank, the second CO2 concentration and the second pH value being measured

Abstract: A method for delivering a processing solution includes providing a concentrated processing solution in a bioprocess container, the concentrated processing solution being produced at a first site. The method also includes combining the concentrated processing solution with a biopolymer containing solution produced in a bioreactor at a second site different from the first site. In some embodiments, the processing solution is a buffer for processing products of cells cultured in a bioreactor. A system and a pharmaceutical production facility for carrying out the method is also provided.

Abstract: Aspects of the present invention relate to a networked cell culture incubator and to methods for operating such an incubator. In one aspect, the cell culture incubator includes a network interface for communicating with a source of parameter data utilized successfully by other incubators. The incubator receives appropriate parameter data and conducts the incubation process as prescribed by the parameter data so as to provide an improved environment for cell culture growth. The incubator may share its own parameter data with the data source for use by other incubators. The incubator and data source may share other forms of data as well.

Abstract: The present invention relates to the field of frozen or dry compositions for prokaryotes, in particular fermentative bacteria such as lactic acid bacteria, a method for preparing frozen or dry prokaryotic compositions and compositions which may be prepared by said method. The cells in a cell concentrate are activated by allowing them to ferment a carbohydrate, before freezing and/or drying to provide a product. The hydrophobicity of the cell surface increases during activation, and this has been found to increase the storage stability of the product.

Abstract: Methods and microorganisms for improved malonyl-CoA flux and production of products having malonyl-CoA as a precursor. The methods comprise dynamically regulating, in a stationary phase of a method, a nitrogen regulatory protein. The methods may dynamically regulate more than one gene.

Abstract: Provided are a recombinant microorganisms having a genetic modification that increases the expression of bacterioferritin, a composition comprising the recombinant microorganism for use in reducing a nitrogen oxide concentration in a sample, and a method of reducing a nitrogen oxide concentration in a sample.

Abstract: Materials and methods to control a nutrient feed in a cell culture process is provided. A sample is received from a bioreactor comprising a cell culture. A viable cell density and a residual nutrient measurement are determined from the received sample. A daily nutrient feeding target is calculated based on the viable cell density and the residual nutrient measurement. The nutrient is fed to the bioreactor according to the calculated daily nutrient feeding target.

Abstract: Saccharide-substituted silk fibroin compositions as well as methods for making and using the same are provided. The compositions can include at least one saccharide coupled to silk fibroin. The coupling can be via various residues on the silk fibroin.

Abstract: The present invention relates to a method and apparatus for passive collection of sperm having improved motility from a semen sample. The semen sample is contacted with on side of a porous barrier and a nutrient-containing media is contacted with the other side of the porous barrier. More robust sperm migrate from the semen sample through the porous barrier and are collected in a nutrient-containing media.

Abstract: The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.

Abstract: The present application provides peripheral blood mononuclear cells comprising an antigen, methods of manufacturing such PBMCs, and methods of using such PBMCs, such as for modulating an immune response in an individual. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.

Abstract: The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells and/or NK cells) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.

Abstract: The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucleic acid sequence encoding a polypeptide that enhances the immune cell function, or a functional derivative thereof in less than 72 hours; engineered cells generated by the methods, compositions comprising said cells and methods of treating a disease or condition using said cells.

Abstract: Genetically modified CCNT1 and XPO1 genes encoding proteins that inhibit virus infection in cells. The genetically modified CCNT1 gene encodes a protein with a C261Y substitution with respect to the human CCNT1 protein. The genetically modified XPO1 gene encodes a protein with P411T, M412V, and/or F414S substitutions with respect to the human XPO1 protein. The genetically modified CCNT1 and XPO1 genes can be introduced in cells. The cells comprising the genetically modified CCNT1 and XPO1 genes can be introduced in a subject with a virus infection to treat the infection.

Abstract: Provided herein are ex vivo methods for expanding regulatory T cells (Tregs), including engineered Tregs, while maintaining their stability and activity. In addition to improving growth and expansion of Tregs, the methods, which can comprise the use of discontinuous stimulation of regulatory T cells (DSORT™), produce Tregs with increased stability and activity.

Abstract: Memory-like cytokine enhanced NK (M-CENK) cells have superior cytotoxicity and can be generated/expanded from a single batch of mononuclear cells to in sufficient quantities to so form a cell-based therapeutic suitable for infusion. Advantageously, the M-CENK cells can be cryopreserved and thawed without compromising viability and cytotoxicity.

Abstract: The method of generating multipotent stem cells is a method for producing and/or expanding multipotent stem cells by delivering at least one reprogramming protein into somatic cells. The at least one reprogramming protein includes a Master Regulator (MR) protein, which may be BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1. The bromodomain protein BAZ2B, in particular, was identified by first generating bi-species heterokaryons by fusing Tcf7l1?/? murine embryonic stem cells (ESCs) with human B-cell lymphocytes. Reprogramming of the B-cell nuclei to a multipotent state was tracked by human mRNA transcript profiling at multiple timepoints. Interrogation of a human B-cell regulatory network with gene expression signatures collected from such reprogramming time series identified eight candidate Master Regulator proteins, which were validated in human cord blood-derived hematopoietic progenitor and lineage-committed cells.

Abstract: A method of manufacturing a stem cell sheets is provided which includes: (a) obtaining mesenchymal stem cells; (b) extracting programmed death ligands one (PD-L1) from the mesenchymal stem cells; (c) selecting only PD-L1 positive (PD-L1+ MSCs) from the PD-L1; (d) differentiating the PD-L1+ cells into osteoblasts and chondroblasts in a predetermined activation condition; and (e) forming the stem cell sheets by mixing the PD-L1+ MSCs with platelet rich plasma solution and CaCl2).

Abstract: A vascularized cardiac organoid with a chamber structure and its preparation method is presented. The cardiac organoids have a unique chamber structure, which includes a myocardium wall. Within the cardiac organoids, a vascular network is developed, enclosed within the myocardium wall. This vascular network is composed of endothelial cells surrounded by smooth muscle cells, forming a network of branched tubular structures. The presence of vasculature significantly promotes the arrangement of the myocardium, enhances the organization of the cardiac cytoskeleton, and promotes the consistency and beating frequency of cardiac cells. The vasculature facilitates the growth and size increase of the cardiac organoids.

Abstract: The present disclosure provides a method for induced differentiation of an extended pluripotent stem cell (EPSC) into a cardiomyocyte and use thereof, and belongs to the technical field of biomedicine. A reagent used for the induced differentiation is a culture medium having definite chemical components, which can obtain cardiomyocytes having high purity and stable between-batch differentiation efficiency. Compared with cardiomyocytes differentiated from existing pluripotent stem cells, the cardiomyocyte obtained has strong early proliferation ability, and more cell number can be obtained; after extended culture and construction into engineering heart microtissue, maturity is higher, the structure is more regularly arranged, and functional contractility is enhanced. Therefore, the present disclosure is a suitable for mechanism research of heart diseases, drug screening, and cell therapy, and thus has excellent practical application value.

Abstract: The present disclosure relates to a non-alcoholic fatty liver artificial tissue model. As compared to a conventional technology by which tissues are cultured only in Matrigel including a device composed of a decellularized liver tissue-derived extracellular matrix and a plurality of microchannels or a decellularized liver tissue-derived extracellular matrix, the present disclosure enables better mimicking of an actual non-alcoholic fatty liver disease due to the presence of Kupffer cells and hepatic stellate cells. Also, according to the present disclosure, the growth of liver organoids can be improved and fat accumulation and inflammation in the liver organoids can be caused to occur well through free fatty acid treatment, and the phenotypes of non-alcoholic fatty liver can be better expressed.

Abstract: Vascularized islets and their preparation method is presented. The vascularized islets are comprised of islet spheroids enclosed within a network of blood vessels. The vascular network is composed of endothelial cells surrounded by smooth muscle cells, forming a tubular vessel with branched structures. The presence of this vasculature significantly enhances the survival of the islets, improves the efficiency of pancreatic precursor cells, islet progenitor cells and R cells, and the increases the synthesis of insulin precursor C-peptide. The procedures for constructing vascularized islets are suitable for long-term in vitro culture of islets.

Abstract: The present disclosure relates to methods of differentiating pluripotent stem cells into endothelial cells. The present disclosure also relates to endothelial cells made by such methods, organoids containing such endothelial cells, and methods of use thereof. The present disclosure also relates to differentiation media for use in the same.

Abstract: Disclosed herein are methods of generating induced pluripotent stem cells. The method involves providing a quantity of somatic or non-embryonic cells, contacting the contacting the somatic or non-embryonic cells with a quantity of one or more programming factors and one or more RNA molecules, and culturing the somatic or non-embryonic cells for a period of time sufficient to generate at least one induced pluripotent stem cell. Various reprogramming factors and RNA molecules for use in the methods are disclosed herein. Also disclosed are cell lines and pharmaceutical compositions generated by use of the methods.

Abstract: The technology described herein relates to compositions and methods for the generation of a primordial NK/T cell, where the produced NK/T primordial cell can subsequently differentiate into T cells or NK cells at an extremely high efficiency and reproducibility. Other aspects relate to genetically modified iPSC cell lines, and method of their use to generate iPSC-derived NK/T primordial cells with a very high yield and high efficiency.

Abstract: There has been demand for an additional method for producing antibodies. The present invention provides: a polymer-coated crosslinked alginate gel fiber in which a core layer containing a crosslinked alginate gel and either antibody-producing cells (e.g., antibody-producing CHO cells) or bioactive-substance-producing cells (e.g., MIN6 cells derived from pancreatic ? cells) is coated with a cationic polymer; and a method for producing antibodies, a bioactive substance, etc., using the fiber.

Abstract: This invention relates to compositions, methods, strategies, and treatment modalities related to the epigenetic modification of hepatitis B virus (HBV) genes.

Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Abstract: The present invention relates to fusion proteins comprising at least two RING domains and a protein targeting domain, and nucleic acid constructs encoding the same suitable for use for protein degradation in cells. The present invention also relates to compositions comprising these fusion proteins and nucleic acids, and the use of the fusion proteins and nucleic acid constructs in therapy.

Abstract: The present invention provides engineered uridine phosphorylase (UP) enzymes, polypeptides having UP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing UP enzymes are also provided. The present invention further provides compositions comprising the UP enzymes and methods of using the engineered UP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Abstract: Provided herein modified dehalogenases have extended surface loop regions that provide a location for internal fusion insertions and modulate binding interaction and activation of environmentally-sensitive chemistries.

Abstract: The present invention relates to the fields of life sciences, micro-organisms and degradation of hydrocarbon chains such as plastics or synthetic polymers. Specifi-cally, the invention relates to an isolated specific enzyme, or a fragment thereof, wherein said enzyme or fragment is capable of degrading a hydrocarbon chain, and to a micro-organism or a host cell comprising the enzyme or a fragment thereof. Also, the present invention relates to a polynucleotide encoding the enzyme or fragment thereof, and to an expression vector or plasmid comprising the polynucleotide of the present invention. And still, the present invention relates to use of the enzyme, fragment, micro-organism, host cell, polynucleotide, expression vector or plasmid of the present invention for degrading a hydrocarbon chain; to a method of degrading a hydrocarbon chain with the specific enzyme or a fragment thereof; and to a method of producing the enzyme or fragment thereof of the present invention.